Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Swedish Orphan Biovitrum AB. (10/24/17). "Press Release: Sobi Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel".

Organisations Organisation Swedish Orphan Biovitrum AB (STO: SOBI)
  Group Swedish Orphan Biovitrum (Sobi) (Group)
  Organisation 2 Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
Products Product pharmaceutical
  Product 2 legal services
Persons Person Hallberg, Torbjörn (Swedish Orphan Biovitrum 201801– General Counsel before Takeda Pharmaceuticals)
  Person 2 Oelkers, Guido (Swedish Orphan Biovitrum 201705– CEo before BSN Medical GmbH + Nycomed)

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the establishment of a new leadership structure; Executive Committee, to replace the Executive Leadership Team in its current form. Sobi also announces the appointment of Torbjörn Hallberg as new General Counsel, Head of Legal Affairs.

The Executive Committee is Sobi’s decision-making body. Regularly, the Executive Committee will be expanded with key functions, to an Extended Leadership Team.

Sobi’s Executive Committee consists of:

Chief Executive Officer – Guido Oelkers
Chief Financial Officer – Mats-Olof Wallin
General Counsel, Head of Legal Affairs – Carin Dahlquist (acting)
Head of EMENAR[i] – Hege Hellström
Head of North America – Rami Levin
Head of Specialty Care – Norbert Oppitz
Head of Medical and Scientific Affairs – Armin Reininger
Head of Haemophilia – Philip Wood
Head of Research & Development, Chief Medical Officer – Milan Zdravkovic

Torbjörn Hallberg joins Sobi from Takeda Pharmaceuticals, where he holds the position as Vice President General Counsel Emerging Markets, heading a legal organisation covering 35 markets. Torbjörn has extensive experience in licensing, mergers and acquisitions. Torbjörn holds a Master of Laws from Lund’s University in Sweden and has more than 15 years’ experience of in-house counsel roles within pharma. Torbjörn will join Sobi in January 2018.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at

For more information please contact

Media relations
Linda Holmström, Senior Communications Manager
+46 70 873 40 95

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
+1 347 224 0819, +1 212 579 0506

[i] Europe, Middle East, North Africa, Russia

Record changed: 2019-06-09


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Swedish Orphan Biovitrum (Sobi) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top